China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange, although specific pricing and additional details remain undisclosed at this time. This strategic move aims to enhance the company’s visibility and funding capabilities in the competitive biotechnology sector.
Innovative Pipeline Focused on Autoimmune Diseases
Founded in June 2015, QYuns specializes in developing antibodies for autoimmune diseases, boasting a robust product pipeline that includes nine drug candidates. Among these, QX002N stands out as a late-stage IL-17A inhibitor, demonstrating promising efficacy in treating ankylosing spondylitis (AS). Meanwhile, QX005N, an IL-4Rα monoclonal antibody, is currently undergoing Phase II clinical trials targeting atopic dermatitis (AD), nodular prurigo (PN), and chronic sinusitis with nasal polyps (CRSwNP) in China.
Commercialization and Strategic Partnerships
QYuns anticipates that its first commercial-stage product will be QX001S, a biosimilar of Johnson & Johnson’s Stelara (ustekinumab). Under a commercialization agreement established in August 2020, Huadong Medicine will manage the marketing of QX001S in China. Additionally, QYuns has partnered with Tigermed (300347.SZ/3347.HK), a China-based Contract Research Organization (CRO), to conduct Phase III clinical studies for QX002N in AS and Phase II studies for QX005N in PN and CRSwNP.
Conclusion: QYuns’ Growth Trajectory in the Biotech Landscape
With its IPO plans and a promising pipeline, Jiangsu QYuns Therapeutics is positioning itself to make a significant impact in the field of autoimmune disease treatment. The company’s strategic partnerships and focus on innovative therapies underscore its commitment to advancing patient care.-Fineline Info & Tech
